Since our data suggests that increased glutamine metabolism drives growth of endocrine resistant breast cancer cells, we measured the protein levels of GLS protein expression in a human breast tumor microarray dataset (Figure 4) that consisted of mostly ER+ tumors; 292 tumors (80%) produced readable data and used in the analysis. This evidence concerns the gene GLS and breast carcinoma.